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MicroRNA-155 is upregulated 
in ascites in patients with 
spontaneous bacterial peritonitis
Philipp Lutz1,2,*, Mohamed M´haimid1,*, Alessandra Pohlmann1, Jennifer Lehmann1, 
Christian Jansen1, Robert Schierwagen1, Sabine Klein1, Christian P. Strassburg1,2, 
Ulrich Spengler1,2 & Jonel Trebicka1,3
MircoRNA’s (miR) have been recognised as important modulators of gene expression and potential 
biomarkers. However, they have been rarely investigated in bio fluids apart from blood. We investigated 
the association of miR-125b and miR-155 with complications of cirrhosis. Ascites was prospectively 
collected from patients with cirrhosis undergoing paracentesis at our department. miR’s were 
determined in the supernatant using qPCR and normalized by SV-40. Clinical parameters were assessed 
at paracentesis and during follow-up. 76 specimens from 72 patients were analysed. MiR’s were not 
associated to age, sex or aetiology of cirrhosis. MiR-125b levels differed between patients with low and 
high MELD score, and miR-125b levels showed an inverse correlation to serum creatinine (r2 = −0.23; 
p = 0.05). MiR-155 was elevated in patients with spontaneous bacterial peritonitis (SBP) (n = 10; 
p = 0.04). MiR-155 levels differed between patients with and without 30-day survival (p = 0.02). No 
association of ascites levels of investigated miR’s to size of varices, episodes of gastrointestinal bleeding 
or hepatorenal syndrome was observed. While miR-125b levels in ascites seem to be associated with 
liver and renal dysfunction, miR-155 might be implicated in local immune response in SBP.
Cirrhosis, as end-stage of any chronic liver injury, is estimated to be the fourth most common cause of death in 
central europe1. Cirrhosis is characterized by fibrosis and distortion of vascular architecture1 leading to increased 
hepatic resistance2, which together with splanchnic hyperperfusion3 causes portal hypertension. Portal hyper-
tension is the driver of complications, such as variceal bleeding and renal dysfunction4. Renal dysfunction and 
splanchnic vasodilation contribute to ascites formation1. Ascites is often complicated by spontaneous bacterial 
peritonitis (SBP), most often caused by bacterial translocation from the intestine5, which might cause renal failure 
and is associated with high mortality.
The existence of microRNA (miR) was first reported in 19936. They were described as small, non-coding 
RNA’s of about 21–25 nucleotides7. They regulate gene expression by binding to messenger RNA (mRNA)8 and 
are thereby implicated in essential biological processes, among them liver disease8 and inflammation9,10. In addi-
tion, due to their size and ability to circulate they are regarded as potential biomarkers for a variety of diseases 
including liver disease11–14. While serum levels of miR’s are accepted biomarkers for liver disease, their levels and 
the potential role as biomarkers in other bio fluids such as ascites are unknown in cirrhosis.
MiR-125b and miR-155 are both involved in macrophage activation10,15, which are next to lymphocytes the 
predominant cell population in ascites16. In murine peritoneal macrophages, miR-125b was upregulated after 
induction of peritonitis and re-stimulation with lipopolysaccharide (LPS); it was identified as a potential mediator 
of tolerance to LPS17. MiR-155 expression increased in peritoneal immune cells in a murine peritonitis model 
after bacterial challenge18 and after intraperitoneal LPS injection19. In addition, miR-155 has been shown to be 
important for antibacterial defence20. Therefore, we analysed the ascites levels of these two miR’s for the first time 
in humans as potential biomarkers for complications in cirrhosis, in particular SBP.
1Department of Internal Medicine I, University of Bonn, Sigmund-Freud-Strasse 25, 53127 Bonn, Germany. 2German 
Center for Infection Research, Partner site Bonn-Cologne, Bonn, Germany. 3Institute of Clinical Research, Faculty 
of Health Sciences, University of Southern Denmark, Campusvej 55, DK-5230 Odense M, Denmark. *These authors 
contributed equally to this work. Correspondence and requests for materials should be addressed to J.T. (email: jonel.
trebicka@ukb.uni-bonn.de)
Received: 18 August 2016
Accepted: 08 December 2016
Published: 11 January 2017
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 7:40556 | DOI: 10.1038/srep40556
Patients and Methods
Patients. Ascites samples from patients with cirrhosis in whom a diagnostic paracentesis was performed at 
the Department of Internal Medicine I of the University Bonn were prospectively collected from March 2012 to 
September 2013. The study was approved by the local ethics committee of Bonn University Medical Centre and 
carried out according to the local guidelines and regulations. Prior to patient inclusion, written informed consent 
was obtained. Patient samples were only included if ascites was due to cirrhosis.
Diagnosis of cirrhosis was confirmed by liver biopsy, where available, or based on the presence of clinical signs 
of portal hypertension (oesophageal varices, splenomegaly and ascites), appropriate findings in ultrasound and 
standard laboratory. Age, sex, aetiology of cirrhosis, Child-Pugh stage, model for end-stage liver disease (MELD) 
score, standard laboratory parameters and complications of cirrhosis (spontaneous bacterial peritonitis, hepato-
renal syndrome, hepatic encephalopathy, variceal bleeding, hepatocellular carcinoma) were recorded. Patients 
were followed-up for a maximum of 365 days. Patients who received a liver transplant were considered dead at 
the day of transplant. Diagnosis of hepatorenal syndrome and grading of esophageal varices was done according 
to current international guidelines21,22.
Ascites specimen of patients with cirrhosis were classified according to international guidelines21 in ascites 
without infection, SBP or control after SBP. Bacterascites was defined by the detection of bacteria in the presence 
of a normal ascites PMN count.
Methods
Standard laboratory parameters (serum albumin, bilirubin, creatinine, C-reactive protein, INR, sodium, total 
blood count, ascites total protein, ascites leukocyte and ascites PMN count) were measured in the central labora-
tory of the university hospital of Bonn with routine procedures. Ten mL of the ascitic fluid were delivered at the 
bedside into aerobic and anaerobic blood culture bottles (BD BACTEC, Becton Dickinson Heidelberg, Germany) 
and incubated for a maximum of 5 days in a Bactec FX blood culture system (Becton Dickinson) for microbial 
studies. Ascites samples were centrifuged at 300 g for 10 minutes. Then the supernatant was stored at − 20 °C until 
MicroRNA-extraction and analysis.
Determination of miR. RNA was isolated from ascites samples using the Qiazol reagent following the 
instructions of the supplier (Qiagen, Hilden, Germany) as previously described12,13. SV40-miR (Qiagen) was 
added to the samples (2 pmol/200 μ l) prior to the RNA isolation procedure for later normalization of the miR 
levels, while RNA quantity was determined by A260-measurement using the ND-1000 NanoDrop spectropho-
tometer (NanoDrop, Wilmington, DE, USA) and quality was assessed by microcapillary electrophoresis (2100 
BioAnalyser, Agilent Technologies, Waldbronn, Germany).
MiR was analyzed by a two-step real-time PCR using the miScript-Reverse Transcription Kit and the 
miRNA-SYBR Green PCR Kit (Qiagen, Hilden, Germany). MiR-125b, miR-155 and SV-40 primers used for 
cDNA synthesis and real-time PCR were selected and purchased from the GeneGlobe Search Center (Qiagen, 
Hilden, Germany). All steps were performed in triplicate and in agreement with the supplier’s guidelines. For 
normalization of the miR levels, spike-in SV40-miRNA (Qiagen, Hilden, Germany) was used. MiR levels are 
expressed as 2−ΔCT with Δ CT being cycle threshold (CT) of the respective miR minus CT of SV-40.
Statistical Analysis. Data are reported as median and range, if not stated otherwise. Statistical analyses were 
performed with IBM SPSS Statistics software version 23 (IBM, New York, USA). For the analysis of quantitative 
data, Mann-U or Wilcoxon signed-rank test were used, as appropriate. Fisher’s exact test was applied to quali-
tative data. For correlation of quantitative data, Spearman’s rank correlation coefficient was calculated. Survival 
was analysed with Kaplan-Meier plots and log-rank test. Patients who received a liver transplant were considered 
as dead at the time of transplant. Contribution of several parameters on ascites miR-155 levels was assessed by a 
forward multiple linear regression model. P < 0.05 was considered significant.
Results
Study cohort. We included 76 ascites specimens of 72 patients with cirrhosis and ascites. The four samples 
acquired during follow-up from the same patients showed difference in infection status (3 times paired SBP/
non-SBP and 1x paired bacterascites/normal ascites). The majority of patients were male (72%), median age was 
62 years. Most patients had cirrhosis due to alcohol abuse (67%) and presented in an advanced stage of liver dis-
ease (53% in Child-Pugh stage C, median MELD score 17). Levels of miR-125b were in general higher than levels 
of miR-155. Further details of the patient cohort are reported in Table 1.
Levels of miR-125b in ascites are inversely associated to a high MELD score and to serum 
creatinine. We correlated the respective miR levels to patients’ age, gender, aetiology and severity of liver 
disease, as well as ascites protein levels (Table 2). We noted a statistical trend towards a low inverse correla-
tion between ascites miR-125b levels and MELD score levels. Therefore, we stratified our patients according to 
a MELD score up to or above the median in our cohort. We observed a significant difference concerning ascites 
miR-125b levels between the two groups (p = 0.02, Fig. 1A). However, no difference in miR-125b level between 
Child-Pugh stage B and C was noted (0.17 vs 0.16 2−ΔCT × 10−3; p = 0.93). Upon closer analysis of the relation 
between MELD score and miR-125b, we found a week borderline correlation between miR-125b and serum cre-
atinine (Fig. 1B, Table 2), but not to serum bilirubin or INR levels. MiR-155 did not correlate to these parameters.
Restriction of analysis to specimens without ascites infection led to comparable results regarding gender, age, 
ascites total protein, MELD score up to/below 17 (p = 0.04), aetiology of cirrhosis and Child-Pugh-stage.
Ascites miR-155 is elevated in SBP. Next, we compared patients with SBP to patients without ascites 
infection (Table 3). In addition to higher ascites PMN counts, patients with SBP were found to have higher serum 
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C-reactive protein levels and higher white blood cell counts compared to patients without SBP. Ascites levels of 
miR-125b did not differ. However, miR-155 was significantly elevated in the ascites of SBP patients (Fig. 2A). In 
bacterascites samples, miR-155 ranged between uninfected ascites and SBP, but failed statistical significance to 
either of these groups due to the small sample size of bacterascites. In every of the available three paired ascites 
samples between SBP and non-SBP, miR-155 decreased in non-SBP compared to SBP (Fig. 2B). In the one patient, 
in whom a paired sample between bacterascites and uninfected ascites was available, levels of miR-155 were 
identical between the two specimens (both 0.08 2−ΔCT × 10−3). We further analysed if miR-155 levels differed 
in non-SBP specimens for patients with previous SBP (n = 21), no (n = 39) or future SBP (n = 6), but levels were 
comparable (Fig. 2C; p = 0.50). To evaluate miR-155 as potential diagnostic test for SBP, we created a receiver 
operator characteristic (ROC) curve. The area under the ROC curve (AUROC) was 0.70 (p = 0.046, Fig. 2D). 
Sensitivity was 90% when using 0.016 2−ΔCT × 10−3 as cut-off, resulting in a low specificity of 37%.
Upon closer analysis of miR-155 levels on features and outcome of SBP patients, there was no difference 
between miR-155 levels between patients with culture positive (n = 4; median miR-155 0.223 2−ΔCT × 10−3) 
versus culture negative SBP (n = 6; median miR-155 0.063 2−ΔCT × 10−3; p = 0.91), between patients with rapid 
Patient cohort
Patient number [n] 72
Age [years ] 62 (56; 69)
Male sex [n] 49 (72)
Aetiology of cirrhosis:
 -Alcohol 48 (67)
 -Viral hepatitis 9 (13)
 -Alcohol + viral Hepatitis 3 (4)
 -Other 12 (16)
Child-Pugh-Score A/B/C [n] 1 (1)/33 (46)/38 (53)
MELD score 17 (13; 24)
Medium-large esophageal varices [n] 20 (28)
History of variceal bleeding [n] 18 (27)
History of hepatorenal syndrome [n] 58 (85)
Previous SBP [n] 24 (33)
Hepatocellular carcinoma [n] 14 (19)
Bilirubin [mg/dl] 2.0 (1; 3.7)
Creatinine [mg/dl] 1.6 (1; 2.5)
International normalized ratio 1.3 (1.1; 1.5)
Platelets [G/L] 150 (112; 228)
Sodium [mmol/L] 136 (133; 140)
Ascites total protein [g/L] 11 (7; 24)
Specimens - without infection/bacterascites/
SBP [n] 62 (82)/4 (5)/10 (13)
miR-125b [2−ΔCT 10−3] 0.2 (0.06; 0.4)
miR-155 [2−ΔCT 10−3] 0.03 (0.01; 0.06)
Table 1.  Characteristics of the patients’ cohort. CT: cycle threshold; MELD: modell for end-stage liver 
disease; miR: microRNA; SBP: spontaneous bacterial peritonitis. Data are given as median (lower; upper 
interquartile) or absolute number (percent).
miR-125b [rho] MiR-155 [rho]
Age 0.03 0.04
Ascites total Protein 0.04 0.13
Serum bilirubin − 0.10 − 0.13
Serum creatinine − 0.23* − 0.03
INR 0.001 − 0.009
MELD − 0.20+ − 0.004
miR-125b [2−ΔCT × 10−3] MiR-155 [2−ΔCT × 10−3]
Gender male/female 0.12/0.18 0.03/0.03
Aetiology alcoholic/viral 0.1/0.2 0.03/0.04
Table 2. Association of ascites miR levels to age, gender, severity and aetiology of liver disease and ascites 
protein levels. +p < 0.1; *p = 0.05; CT: cycle threshold; INR: International normalized ratio; MELD: model 
for end-stage liver disease; miR: microRNA. Data are given as spearman’s correlation coefficient or as median. 
Statistical analysis with spearman’s rank correlation or Wilcoxon-Mann-Whitney-U test.
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treatment response to SBP versus none/delayed response (n = 5 each; median miR-155 0.071 2−ΔCT × 10−3 versus 
0.055 2−ΔCT × 10−3; p = 1.0) and between SBP patients with (n = 8) versus without (n = 2) concomitant acute 
kidney failure (median miR-155 0.091 2−ΔCT × 10−3 versus 0.063 2−ΔCT × 10−3). However, when we stratified SBP 
patients according to 30-day survival, ascites miR-155 levels were lower in non-survivors (n = 4) compared to 
survivors (n = 6, median 0.019 2−ΔCT × 10−3 versus 0.228 2−ΔCT × 10−3; p = 0.02).
Ascites miR’s were not associated to hepatorenal syndrome or variceal bleeding. Next, we 
investigated if levels of ascites miRNA’s were associated to a history of variceal bleeding, presence of medium to 
large varices or hepatorenal syndrome. No statistically significant association was found (Table 4).
Ascites miR’s and presence of hepatocellular carcinoma. When we analysed the association between 
ascites miRNA levels and presence of hepatocellular carcinoma (HCC), we found no association for miR-125b 
(Fig. 3A), but a statistical trend for miR-155. When we excluded patients with ascites infection, we detected 
significantly lower ascites miR-155 levels in patients with HCC compared to patients without HCC (Fig. 3B). In 
multivariate analysis, considering SBP and HCC as potential contributors to ascites miR-155 levels, only SBP was 
found to contribute significantly to miR-155 levels (standardized Beta: 0.494; p < 0.001).
Survival. No significant difference in 180 day and one year survival was detected when patients were stratified 
according to the median of the respective miR.
Discussion
In this pilot study, we evaluated associations of ascites miR levels to common complications of chronic liver 
disease. By using ascites as bio fluid, we chose a compartment located directly next to the diseased organ, which 
might reflect disease better than peripheral blood, but which is easily accessible in patients with cirrhosis. We 
analysed miR-125b and miR-155, which have been involved in macrophages activation15 and regulation of innate 
immunity responses9. To our knowledge, we provide the first data on ascites microRNA levels in chronic liver 
disease.
Figure 1. (A) Ascites microR-125b levels differ between patients stratified for the MELD score. Means of ascites 
microR-125b levels with error bars reflecting 2x standard error of the mean. MELD: model of end-stage liver 
disease, miR: microRNA. Statistical analysis with Mann-Whitney-U test. (B) Correlation between ascites miR-
125b and serum creatinine miR: microRNA; Statistical analysis with spearman’s rank correlation.
Uninfected ascites SBP p
Number of specimens 62 10
Culture positive 0 4 (40)
Detected microorganisms 0
2 × Escherichia coli
1 × Enterobacter cloacae
1 × Enterococcus faecium
C-reactive protein [mg/dL] 17 (11; 32) 104 (60; 174) < 0.001
White blood cell count [G/L] 7.6 (6.2; 10.5) 9.5 (8.5; 13.6 ) 0.02
Ascites PMN count [/μ L] 24 (9; 54) 1237 (552; 3947) < 0.001
MiR-125b [2−ΔCT × 103] 0.16 (0.06; 0.37) 0.11 (0.06; 0.24) 0.59
MiR-155 [2−ΔCT × 103] 0.03 (0.01; 0.05) 0.06 (0.02; 0.4) 0.04
Table 3.  Clinical markers of inflammation and ascites miR levels in patients with and without 
spontaneous bacterial peritonitis. CT: cycle threshold; MELD: model for end-stage liver disease; miR: 
microRNA; SBP: spontaneous bacterial peritonitis. Data are given as median (lower; upper interquartile) 
absolute number (percent). Statistical analysis with Mann-Whitney-U test.
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MiR-125b levels were different in patients with high and low MELD as indicator of liver disease severity. 
However, we did not detect any difference applying Child-Pugh stages as another method for assessing severity 
of liver disease. Since most of our patients ranged quite similar on the Child-Pugh stages, the MELD score might 
have been more discriminative. However, miR-125b levels correlated lowly, but significantly to serum creatinine. 
A negative correlation between miR-125b and kidney function has already been reported before23. In addition, 
miR-125b negatively regulates expression of the protective angiotensin-converting enzyme 2 in renal tubular 
epithelial cells, thereby mediating kidney damage to high glucose levels24. Because creatinine is one of the three 
parameters used to calculate the MELD score25, it is likely that the difference in miR levels between high and 
low MELD scores did not reflect an association to liver disease severity, but rather the difference in kidney func-
tion. As expected, serum creatinine levels were significantly different between high and low MELD scores in 
our cohort (median serum creatinine 2.5 versus 1.2 mg/dL; p < 0.001). Low blood miR-125b levels have been 
linked to decreased miR-125b expression in smooth vascular cells in kidney disease23. To what extent vascular 
cells account for miR-125b blood levels is not known. Although miR-125b is expressed at significantly higher 
Figure 2. (A) Ascites miR-155 was elevated in patients with spontaneous bacterial peritonitis. Means of 
ascites microRNA-155 levels with error bars reflecting 2x standard error of the mean for uninfected ascites 
(n = 62), bacterascites (n = 4) and SBP (n = 10) specimens. SBP: spontaneous bacterial peritonitis; Statistical 
analysis with Mann-Whitney-U test. (B) Ascites miR-155 increased during spontaneous bacterial peritonitis 
intraindividually. Ascites microRNA-155 at time of SBP and without SBP. miR: microRNA; SBP: spontaneous 
bacterial peritonitis; statistical analysis with Wilcoxon signed-rank test. (C) Ascites miR-155 was comparable 
in patients regardless of history/future occurrence of spontaneous bacterial peritonitis. Ascites microRNA-155 
levels in patients stratified for previous SBP (n = 21), no SBP (n = 39) or SBP during follow-up (n = 6). miR: 
microRNA; SBP: spontaneous bacterial peritonitis. Statistical analysis with Mann-Whitney-U test; p = n.s.  
(D) Receiver operator characteristic curve for miR-155 as diagnostic test for spontaneous bacterial peritonitis. 





History of variceal bleeding yes/no 0.1/0.19 0.03/0.04
Esophageal varices small/medium-large 0.23/0.14 0.04/0.02
History of hepatorenal 
syndrome yes/no 0.17/0.15 0.03/0.03
Table 4.  Association of ascites miR levels to variceal bleeding, size of esophageal varices and hepatorenal 
syndrome. Data are given as median. Statistical analysis with Mann-Whitney-U test.
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amounts in macrophages compared to other immune cells and mediates activation of macrophages15, the con-
tribution of macrophages to systemic or peritoneal miR-125b levels might be low compared to vascular cells. 
Additionally, miR-125b expression in macrophages might be the results of complex opposing effects in patients 
with cirrhosis, who usually have elevated LPS levels26, because first exposure to LPS down-regulates miR-125b in 
macrophages17,27, but re-stimulation to LPS up-regulates miR-125b expression, linking miR-125b to LPS toler-
ance17. SBP is a trigger for the development of renal failure28,29, as well as circulatory and inflammatory changes 
are preceding the development of organ failure in context of acute-on-chronic liver failure30, although the exact 
mechanism is not fully understood. MiR-125b might be one of the mediators, which might be linked to kidney 
dysfunction in the situation of bacterial translocation. Although the present study is far from proving this link, it 
might strongly suggest it and initiate further research.
Ascites miR-155 was significantly upregulated during SBP in our patients. Similar to our observation in 
humans, establishing peritonitis by intraperitoneal injection of Klebsiella pneumoniae resulted in local upreg-
ulation of miR-155 in mice31. Upregulation was more pronounced in a similar peritonitis mouse model after 
pre-treatment with LPS18, which might mimic the state of enhanced bacterial translocation of a cirrhotic patient 
before SBP develops26. MiR- 155 increased after peritonitis induction and was again associated with immune 
dysregulation in another mouse model assessing the effect of hypothermia on immune dysregulation19. MiR-155 
has been involved in various mechanism of immune response, comprising maturation of B lymphocytes, respon-
siveness of B lymphocytes to B-cell receptor ligation32, promotion of a Th1 phenotype33, enhancing antibacterial 
defense mechanisms of CD8 T cells34, proliferation of myeloid cells and inflammatory cytokine secretion9. 
In MiR-155 knock-out mice, immunity against enteric infections such as Salmonella and Citrobacter35 is 
impaired. Interestingly, miR-155 is not only induced by activation of extracellular receptors for bacterial prod-
ucts, such as toll-like receptor 4, but also by intracellular receptors such as nucleotide-binding oligomerization 
domain-containing protein 2 (NOD2)36. Polymorphisms in the NOD2 gene have been linked to susceptibility 
to SBP and to mortality in patients with cirrhosis and ascites37. Therefore, miR-155 might be an immunological 
mechanism which is initiated early in the response to ascites infection and therefore represent a novel marker of 
SBP. Interestingly, low miR-155 levels during SBP were associated with decreased short time survival. Relatively 
low miR-155 levels during SBP might reflect inability of the host to mount an adequate immune response to bac-
terial infection and thus explain the unfavourable outcome. Still, these findings must be validated and investigated 
in further studies.
MicroRNA’s are considered to be potential drug targets by anti-microRNA oligonucleotides38. As a proof of 
concept, anti-miR-122 has been applied safely in patients with chronic hepatitis C and shown excellent treatment 
success39. Inhibition of miR-155 was feasible in a mouse modell40. Further investigation of the role of miR-155 in 
peritoneal immune response and immune dysregulation in cirrhotic patients will be eminent to evaluate its role 
as a potential drug target that would even allow local application into the ascites in patients with SBP.
Dysregulation of microRNA’s is a common finding in malignant tumours41 and has been reported for hepa-
tocellular carcinoma42. The particular role of microRNA’s, however, seems to be complex and depending on the 
tumor entity. For example, miR-125b has been shown to be upregulated in tissue of gastric cancer and to enhance 
spread of gastric cancer metastases43, but to inhibit formation of metastases in hepatocellular carcinoma44. We did 
not aim to assess a potential relation between ascites microRNA and malignancy in our study. Still, we found an 
association between miR-155 and presence of hepatocellular carcinoma, which, however, was lost upon multivar-
iate analysis. Ascites is not a suitable bio fluid to screen for hepatocellular carcinoma, because treatment options 
are limited once patients have developed ascites due to advanced liver disease45.
Figure 3. (A) Ascites microRNA-125b was comparable between patients with and without hepatocellular 
carcinoma. Means of ascites microRNA-125b levels with error bars reflecting 2x standard error of the mean 
for patients with (n = 14) and without (n = 58) hepatocellular carcinoma. HCC: hepatocellular carcinoma; 
Statistical analysis with Mann-Whitney-U test. (B) Ascites microRNA-155 was downregulated in hepatocellular 
carcinoma patients without ascites infection. Means of ascites microRNA-155 levels with error bars reflecting 2x 
standard error of the mean for ascites specimens without infection in patients with (n = 11) and without (n = 51) 
hepatocellular carcinoma. HCC: hepatocellular carcinoma; Statistical analysis with Mann-Whitney-U test.
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We present a single centre pilot study on ascites miRNA. Further studies including larger patient numbers are 
needed to confirm our findings.
In conclusion, we provide first data on ascites microRNA levels in patients with advanced liver disease, indi-
cating that microRNA’s might be implicated in the pathogenesis of bacterial ascites infections. If our results can 
be confirmed in larger patient series, miR-155 might be an interesting target to modify immune response during 
bacterial infections in patients with cirrhosis.
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